Multiple biomarkers in molecular oncology. II. Molecular diagnostics applications in breast cancer management

References

• Loprinzi C, Thome SD. Understanding the utility of adjuvant systematic therapy for primary breast cancer. J. Clin. Oncol.19, 972–979 (2001).
   PubMed Web of Science ®Google Scholar
• Fitzgibbons PL, Page Dl, Weaver D et al. Prognostic factors in breast cancer: College of American Pathologists consensus statement 1999. Arch. Pathol. Lab. Med.124, 966–978 (2000).
   PubMed Web of Science ®Google Scholar
• Goldhirsch A, Glick JH, Gelber RD et al. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann. Oncol.16, 1569–1583 (2005).
   PubMed Web of Science ®Google Scholar
• Cianfrocca M, Goldstein LJ. Prognostic and predictive factors in early-stage breast cancer. Oncologist9, 606–616 (2004).
   PubMed Web of Science ®Google Scholar
• Esteva FJ, Hortobagyi GN. Prognostic molecular markers in early breast cancer. Breast Cancer Res.6(3), 109–118 (2004).
   PubMed Web of Science ®Google Scholar
• Yamashita H, Nishio M, Toyama T et al. Coexistence of Her-2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer. Breast Cancer Res.6, R24–R30 (2004).
   PubMed Web of Science ®Google Scholar
• Duffy MJ. Urokinase plasminogen activator and its inhibitor, PAI-1, as prognostic markers in breast cancer: from pilot to level 1 evidence studies. Clin. Chem.48, 1194–1197 (2002).
   PubMed Web of Science ®Google Scholar
• Shinozaki M, Hoon DS, Giuliano AE et al. Distinct hypermethylation profile of primary breast cancer is associated with sentinel lymph node metastasis. Clin. Cancer Res.11(6), 2156–2162 (2005).
   PubMed Web of Science ®Google Scholar
• Takahashi Y, Miyoshi Y, Takahata C et al. Down-regulation of LATS1 and LATS2 mRNA expression by promoter hypermethylation and its association with biologically aggressive phenotype in human breast cancers. Clin. Cancer Res.11(4), 1380–1385 (2005).
   PubMed Web of Science ®Google Scholar
• Zhang Z, Yamashita H, Toyama T et al. NCOR1 mRNA is an independent prognostic factor for breast cancer. Cancer Lett.237(1), 123–129 (2006).
   PubMedGoogle Scholar
• Watkins G, Douglas-Jones A, Bryce R, Mansel RE, Jiang WG. Increased levels of SPARC (osteonectin) in human breast cancer tissues and its association with clinical outcomes. Prostaglandins Leukot. Essent. Fatty Acids72(4), 267–272 (2005).
   PubMed Web of Science ®Google Scholar
• Davies MP, O’Neill PA, Innes H et al. Correlation of mRNA for oestrogen receptor β splice variants ERβ1, ERβ2/ERβcx and ERβ5 with outcome in endocrine-treated breast cancer. J. Mol. Endocrinol.33(3), 773–782 (2004).
   PubMedGoogle Scholar
• Chotteau-Lelievre A, Revillion F, Lhotellier V et al. Prognostic value of ERM gene expression in human primary breast cancers. Clin. Cancer Res.10(21), 7297–7303 (2004).
   PubMedGoogle Scholar
• Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumors. Nature406(6797), 747–752 (2000).
   PubMed Web of Science ®Google Scholar
• Sorlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl Acad. Sci. USA98(19), 10869–10874 (2001).
   PubMed Web of Science ®Google Scholar
• West M, Blanchette C, Dressman H et al. Predicting the clinical status of human breast cancer by gene expression profiles. Proc. Natl Acad. Sci. USA98(20), 11462–11467 (2001).
   PubMed Web of Science ®Google Scholar
• Sorlie T, Tibshirani R, Parker J et al. Repeated observations of breast tumor subtypes in independent gene expression data sets. Proc. Natl Acad. Sci. USA100(14), 8418–8423 (2003).
   PubMed Web of Science ®Google Scholar
• Sotiriou C, Neo SY, McShane LM et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc. Natl Acad. Sci. USA100(18), 10393–10398 (2003).
   PubMed Web of Science ®Google Scholar
• van’t Veer LJ, Dai H, van de Vijver MJ et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature415(6871), 530–536 (2002).
   PubMed Web of Science ®Google Scholar
• van de Vijver MJ, Hem YD, van’t Veer LJ et al. A gene-expression signature as a predictor of survival in breast cancer. N. Eng. J. Med.347(25), 1999–2009 (2002).
   PubMed Web of Science ®Google Scholar
• van de Rijn M, Perou CM, Tibshirani R et al. Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am. J. Pathol.161(6), 1991–1996 (2002).
   PubMed Web of Science ®Google Scholar
• Nielson TO, Hsu, FD, Jensen K et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast cancer. Clin. Cancer Res.10(16), 5367–5374 (2004).
   PubMedGoogle Scholar
• Sorlie T. Molecular portraits of breast cancer: tumour subtypes as distinct disease entities. Eur. J. Cancer40(18), 2667–2675 (2004).
   PubMed Web of Science ®Google Scholar
• Gruvberger S, Ringner M, Chen Y et al. Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Res.61(16), 5979–5984 (2001).
   PubMed Web of Science ®Google Scholar
• Pusztai L, Ayers M, Stec J, Clark E et al. Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors. Clin. Cancer Res.9(7), 2406–2415 (2003).
   PubMed Web of Science ®Google Scholar
• Miller DV, Leontovich AA, Lingle WL et al. Utilizing Nottingham Prognostic Index in microarray gene expression profiling of breast carcinomas. Mod. Pathol.17(7), 756–764 (2004).
   PubMedGoogle Scholar
• Yu K, Lee CH, Tan PH et al. A molecular signature of the Nottingham prognostic index in breast cancer. Cancer Res.64(9), 2962–2968 (2004).
   PubMed Web of Science ®Google Scholar
• Sotiriou C, Wirapati P, Loi S et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J. Natl Cancer Instit.98(4), 262–272 (2006).
   PubMed Web of Science ®Google Scholar
• Canales RD, Luo Y, Willey JC et al. Evaluation of DNA microarray results with quantitative gene expression platforms. Nat. Biotechnol.24(9), 1115–1122 (2006).
   PubMed Web of Science ®Google Scholar
• Glas Am, Floore A, Delahaye L et al. Converting a breast cancer microarray signature into a high-throughput diagnostic test. BMC Genomics7, 278 (2006).
   PubMed Web of Science ®Google Scholar
• Buyse M, Loi S, van’t Veer L et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J. Natl Cancer Instit.98(17), 1183–1192 (2006).
   PubMed Web of Science ®Google Scholar
• Paik S, Shak S, Tang G et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med.351(27), 2817–2826 (2004).
   PubMed Web of Science ®Google Scholar
• Esteva FJ, Sahin AA, Cristofanilli M et al. Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy. Clin. Cancer Res.11(9), 3315–3319 (2005).
   PubMed Web of Science ®Google Scholar
• Cobleigh MA, Tabesh B, Bitterman P et al. Tumor gene expression and prognosis in breast cancer patients with 10 or more positive lymph nodes. Clin. Cancer Res.11(24), 8623–8631 (2005).
   PubMed Web of Science ®Google Scholar
• Habel LA, Shak S, Jacobs MK et al. A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res.8(3), R25 (2006).
   PubMed Web of Science ®Google Scholar
• Kaklamini V. A genetic signature can predict prognosis and response to therapy in breast cancer. Expert Rev. Mol. Diagn.6(6), 803–806 (2006).
   PubMedGoogle Scholar
• Ma X-J, Wang Z, Ryan PD et al. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell5, 607–616 (2004).
   PubMed Web of Science ®Google Scholar
• Reid JF, Lusa L, De Cocco L et al. Limits of predictive models using microarray data for breast cancer clinical treatment outcome. J. Natl Cancer Instit.97(12) 927–930 (2005).
   PubMed Web of Science ®Google Scholar
• Jansen M, Foekens JA, Klijn J, Berns E. Re: limits of predictive models using microarray data for breast cancer clinical treatment outcome. J. Natl Cancer Instit.97(24) 1851–1853 (2005).
   PubMedGoogle Scholar
• Goetz MP, Suman VJ, Ingle JN et al. A two gene expression ratio of homeobox13 and interleukin-17B receptor for prediction of recurrence and survival in women receiving adjuvant tamoxifen. Clin. Cancer Res.12(7), 2080–2087 (2006).
   PubMed Web of Science ®Google Scholar
• Ma X-J, Hilsenbeck SG, Wang W et al. The HoxB13:IL17BR expression index is a prognostic factor in early stage breast cancer. J. Clin. Oncol.24(28), 4611–4619 (2006).
   PubMed Web of Science ®Google Scholar
• Jacquemier J, Ginestier C, Rougemont J et al. Protein expression profiling identifies subclasses of breast cancer and predicts prognosis. Cancer Res.65(3), 767–779 (2005).
   PubMed Web of Science ®Google Scholar
• Makretsov NA, Huntsman DG, Nielsen TO et al. Hierarchical clustering analysis of tissue microarray immunostaining data identifies prognostically significant groups of breast carcinoma. Clin. Cancer Res.10(18 Pt 1), 6143–6151 (2004).
   PubMed Web of Science ®Google Scholar
• Ring BZ, Seitz RS, Beck R et al. Novel prognostic immunohistochemical biomarker panel for estrogen receptor-positive breast cancer. J. Clin. Oncol.24(19), 3039–3047 (2006).
   PubMed Web of Science ®Google Scholar
• Whitehead CM, Nelson R, Hudson R et al. Selection and utility of a panel of early stage breast cancer prognostic molecular markers. Mod. Pathol.18(Suppl 1), 55A (2005).
   Google Scholar
• Ross JS, Boguniewicz AB, Ross MS et al. Predicting prognosis in early stage primary breast cancer using a five biomarker panel and image assisted immunohistochemistry (IHC) scoring. Breast Cancer Res. Treat.94(Suppl. 1), 3019A (2005).
   Google Scholar
• Davol PA, Bagdasaryan R, Elfenbein GJ, Maizel AL, Frackelton AR Jr. Shc proteins are strong, independent prognostic markers for both node-negative and node-positive primary breast cancer. Cancer Res.63(20), 6772–6783 (2003).
   PubMed Web of Science ®Google Scholar
• Frackelton AR Jr, Lu L, Davol PA, Bagdasaryan R, Hafer LJ, Sgroi DC. p66 Shc and tyrosine-phosphorylated Shc in primary breast tumors identify patients likely to relapse despite tamoxifen therapy. Breast Cancer Res.8(6), R73 (2006).
   Google Scholar
• Backus J, Laughlin T, Wang Y et al. Identification and characterization of optimal gene expression markers for detection of breast cancer. J. Mol. Diagn.7(3), 327–336 (2005).
   PubMed Web of Science ®Google Scholar
• Nissan A, Jager D, Roystacher M et al. Multimarker RT-PCR assay for the detection of minimal residual disease in sentinel lymph nodes of breast cancer patients. Br. J. Cancer94(5), 681–685 (2006).
   PubMedGoogle Scholar
• van Diest PJ, van der Wall E, Baak JPA. Prognostic value of proliferation in invasive breast cancer: a review. J. Clin. Pathol.57(7), 675–681 (2004).
   PubMed Web of Science ®Google Scholar
• Shen R, Ghosh D, Chinnaiyan AM. Prognostic meta-signature of breast cancer developed by two-stage mixture modeling of microarray data. BMC Genomics5(1), 94 (2004).
   PubMed Web of Science ®Google Scholar
• Milyavsky M, Tabach Y, Shats I et al. Transcriptional programs following genetic alterations in p53, INK4A, and H-Ras genes along defined stages of malignant transformation. Cancer Res.65(11), 4530–4543 (2005).
   PubMed Web of Science ®Google Scholar
• Fritz P, Cabrera CM, Dippon J et al. c-erbB2 and topoisomerase IIα protein expression independently predict poor survival in primary human breast cancer: a retrospective study. Breast Cancer Res.7, R374–R384 (2005).
   Web of Science ®Google Scholar
• Gonzalez MA, Pinder SE, Callagy G et al. Minichromosome maintenance protein 2 is a strong independent prognostic marker in breast cancer. J. Clin. Oncol.21(23), 4306–4313 (2003).
   PubMed Web of Science ®Google Scholar
• Gonzalez MA, Tachibana KE, Chin SF et al. Geminin predicts adverse clinical outcome in breast cancer by reflecting cell-cycle progression. J. Pathol.204(2), 121–130 (2004).
   PubMed Web of Science ®Google Scholar
• Rudolph P, Kuhling H, Alm P et al. Differential prognostic impact of the cyclins E and B in premenopausal and postmenopausal women with lymph node-negative breast cancer. Int. J. Cancer105(5), 674–680 (2003).
   PubMed Web of Science ®Google Scholar
• Kuhling H, Alm P, Olsson H et al. Expression of cyclins E, A, and B, and prognosis in lymph node-negative breast cancer. J. Pathol.199(4), 424–431 (2003).
   PubMed Web of Science ®Google Scholar
• Winters ZE, Hunt NC, Bradburn MJ et al. Subcellular localisation of cyclin B, Cdc2 and p21(WAF1/CIP1) in breast cancer. association with prognosis. Eur. J. Cancer37(18), 2405–2412 (2001).
   PubMed Web of Science ®Google Scholar
• Xia W, Chen J-S, Zhou X et al. Phosphorylation/cytoplasmic localization of p21 Cip1/Waf1 is associated with HER2/neu overexpression and provides a novel combination predictor for poor prognosis in breast cancer patients. Clin. Cancer Res.10(11), 3815–3824 (2004).
   PubMed Web of Science ®Google Scholar
• Viglietto G, Motti ML, Bruni P et al. Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27Kip1 by PKB/Akt-mediated phosphorylation in breast cancer. Nat. Med.8(10), 1136–1144 (2002).
   PubMed Web of Science ®Google Scholar
• Liang J, Zubovitz J, Petrocelli T et al. PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. Nat. Med.8(10), 1153–1160 (2002).
   PubMed Web of Science ®Google Scholar
• Daidone MG, Silvestrini R. Prognostic and predictive role of proliferation indices in adjuvant therapy of breast cancer. J. Natl Cancer Inst. Monogr.30, 27–35 (2001).
   PubMedGoogle Scholar
• Glinsky GV, Berezovska O, Glinskii AB. Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J. Clin. Invest.115(6), 1503–1521 (2005).
   PubMed Web of Science ®Google Scholar
• Dressler LG, Berry DA, Broadwater G et al. Comparison of HER2 status by fluorescence in situ hybridization and immunochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients. J. Clin. Oncol.23(19), 4287–4297 (2005).
   PubMed Web of Science ®Google Scholar
• Ayers M, Symmans WF, Stec J et al. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin and cyclophosphamide chemotherapy in breast cancer. J. Clin. Oncol.22(12), 2284–2293 (2004).
   PubMed Web of Science ®Google Scholar
• Iwao-Koizumi K, Matoba R, Ueno N et al. Prediction of docetaxel response in human breast cancer by gene expression profiling. J. Clin. Oncol.23(3), 422–431 (2005).
   PubMed Web of Science ®Google Scholar
• Chang JC, Wooten EC, Tsimelzon A et al. Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients. J. Clin. Oncol.23(6), 1169–1177 (2005).
   PubMed Web of Science ®Google Scholar
• Jansen MP, Foekens JA, van Staveren IL et al. Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling. J. Clin. Oncol.23(4), 732–740 (2005).
   PubMed Web of Science ®Google Scholar
• Hannemann J, Oosterkamp HM, Bosch CAJ et al. Changes in gene expression associated with response to neoadjuvant chemotherapy in breast cancer. J. Clin. Oncol.23(15), 3331–3342 (2005).
   PubMed Web of Science ®Google Scholar
• Modlich O, Prisack HB, Munnes M, Audretsch W, Bojar H. Predictors of primary breast cancers responsiveness to preoperative epirubicin/cyclophosphamide-based chemotherapy: translation of microarray data into clinically useful predictive signatures. J. Transl. Med.3(1), 32 (2005).
   PubMed Web of Science ®Google Scholar
• Rouzier R, Perou CM, Symmans WF et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin. Cancer Res.11(16), 5678–5685 (2005).
   PubMed Web of Science ®Google Scholar
• Rouzier R, Rajan R, Wagner P et al. Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. Proc. Natl Acad. Sci. USA102(23), 8315–8320 (2005).
   PubMed Web of Science ®Google Scholar
• Gianni L, Zambetti M, Clark K et al. Gene expression profiles in a paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J. Clin. Oncol.23(29), 7265–7277 (2005).
   PubMed Web of Science ®Google Scholar
• Paik S, Tang G, Shak S et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J. Clin. Oncol.24(23), 3726–3734 (2006).
   PubMed Web of Science ®Google Scholar
• Fan C, Oh DS, Wessels L et al. Concordance among gene-expression based predictors for breast cancer. N. Engl. J. Med.355(6), 560–569 (2006).
   PubMed Web of Science ®Google Scholar
• Massague J. Sorting our breast-cancer gene signatures. N. Engl. J. Med.356(3), 294–297 (2007).
   PubMed Web of Science ®Google Scholar
• Bast RC, Lilja H, Urban N et al. Translational crossroads for biomarkers. Clin. Cancer Res.11(17), 6103–6108 (2005).
   PubMed Web of Science ®Google Scholar